Please login to the form below

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.

Cell and gene therapies represent a paradigm shift in the development of pharmaceutical products.

Not only do these treatments often promise to cure disease, they also represent an evolution in the manufacture and delivery of products. As a result, cell and gene therapies are synonymous with complexity.

Manufacturers developing cell and gene therapies face a steeper climb to commercialization compared with traditional biopharmaceutical products. While there is significant innovation in this space, few cell and gene therapies reach the market.

Additionally, those that do have been marred by supply chain and manufacturing challenges, along with healthcare infrastructure barriers, including a lack of treatment sites for administering therapies.

These factors affect the scalability of these products and the patient and healthcare professional experience. Add to this a fast-paced global policy and regulatory landscape in which policymakers and regulators struggle to upskill fast enough to keep up with the evolving high science. Payers require more support than ever to understand the novel data and make decisions regarding these therapies.

Patients and healthcare professionals alike are entranced by the promise of the treatments but require support in understanding the risks and benefits of novel cell and gene therapies.

Understanding the barriers and risks early in drug development is paramount for ensuring these therapies deliver on their promises for patients.

Drawing on our experience working with biopharmaceutical innovators on the commercialization and launch of cell and gene therapies, we have developed a series of articles on the evolving landscape, which we present in this publication.

Read on to learn about:

  • An interview with Professor Francesco Dazzi, Medical Lead Cell Therapy, BioPharmaceuticals R&D at AstraZeneca, on the company’s novel cell therapy pipeline for chronic diseases
  • Patient and market access insights on leveraging CRISPR technology for hematologic diseases
  • The evolving policy and regulatory landscape for cell and gene therapies
  • Trends shaping the future of personalized medicine
  • Steps for communicating the complex science to a variety of stakeholders

3rd November 2022



Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

No. 3 Booths Park
Booths Hall
Chelford Road
WA16 8GS
United Kingdom

Latest content on this profile

Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer
Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.
Fishawack Health
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts provide insights on the trends, challenges and opportunities for biopharmaceutical companies, including why an interdisciplinary approach is needed to improve outcomes in oncology.
Fishawack Health
The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of innovative pricing models, including ensuring the model chosen meets the payer’s needs.
Fishawack Health
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?
Fishawack Health
Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health